fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-08-11
Biotech partner: PregLem (Switzerland)
Pharma Partner: Merck Serono (Germany- Switzerland)
Type of agreement: * licensing
Compound: Bentamapimod (orally active Jun Kinase Inhibitor, JNK-I AS602801)
Disease area: prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception
Development phase: preclinical. This anti-inflammatory agent has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative adhesions. Preclinical data show that the compound is an effective anti-inflammatory with anti-fibrotic properties.
Nature of the agreement: PregLem has concluded a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception. PregLem plans to initiate a clinical proof of concept study and a phase II study during 2011 for the prevention of post-surgical abdominal adhesions and/or endometriosis in patients with tubal ligation or comparable effective contraception.


Financial terms of the agreement: Financial details were not disclosed.


Go back to previous page